Targeting tau: where dementia science stands

Tau is a protein that normally stabilises nerve cells. In tauopathies, a group of brain diseases involving abnormal tau accumulation, the protein becomes chemically altered. It loses its stabilising function and clumps into structures that damage neurons. Tauopathies include Alzheimer’s disease, frontotemporal dementia, and progressive supranuclear palsy.

The review surveys current therapeutic strategies. Researchers are targeting tau through several routes: reducing tau production, preventing aggregation, promoting its breakdown, and neutralising damaged tau forms using antibodies. Each approach carries its own challenges.

What goes wrong with tau

The most characteristic change in tauopathies is hyperphosphorylation: too many phosphate groups attach to tau. As a result, it no longer binds properly to the internal scaffolding of neurons and aggregates into neurofibrillary tangles. These tangles appear to contribute to neuronal death, though the precise mechanism is still under investigation.

The comparison with amyloid-beta is instructive. Decades of research and billions in investment produced drugs that clear amyloid from the brain, but clinical benefits for patients have remained limited. The authors expect the path to tau therapies to be similarly difficult.

No approved treatment yet

There is currently no broadly effective tau-directed treatment available. Several candidate drugs are in clinical trials, but none has yet produced convincing results. The authors emphasise that the biochemistry of tau aggregates is complex and not yet fully understood.

From a longevity perspective, this review illustrates the distance between a promising mechanism and a working therapy. Tauopathies represent one of the most important unsolved problems in aging biology.

Read the original article